Citations

Clear

1727 citation(s) found for "Fu, Alan".

Association of androgen receptor variant 9 (AR-V9) mRNA expression levels in metastatic tissue with resistance to abiraterone acetate/prednisone (AA/P).
Sicotte, Hugues , Carlson, Rachel E. , Tan, Winston , Wu, Kevin J. , Eiken, Patrick W. , Jiménez, Rafael E. , Cernigliaro, Joseph G. , Costello, Brian A. , Pitot, Henry C., Moynihan, Timothy J. , Wang, Liewei , Kohli, Manish , Hillman, David W. , Wang, Liguo , Li, Ying , Quevedo, Fernando , Ho, Thai H. , Bryce, Alan H. , Dehm, Scott M.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 5036-5036

10.1200/jco.2016.34.15_suppl.5036 Get It

GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002).
Evans, T.R. Jeffry , Nakamura, Kenichi , Honma, Yoshitaka , Tije, Albert J. ten , Anthoney, David Alan, Boyd, Ruth , Graham, Janet , Nicoll, J. J., Salto‐Tellez, Manuel , Starling, Naureen , Ueno, Makoto , Yim, Kein, Aparicio, Thomas , Malicot, Karine Le , McWilliams, Robert R. , Dixon-Hughes, Judith , Iveson, Timothy , Paul, James , Yim, Kein-Leong , Bridgewater, John , Wilson, Richard H.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS4154-TPS4154

10.1200/jco.2016.34.15_suppl.tps4154 Get It

Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8).
Kaubisch, Andreas , Posey, James , Tan, Benjamin , Kavan, Petr , Goel, Rakesh, Lammers, Philip E. , Rajdev, Lakshmi , Kelley, Robin Kate , Siegel, Abby B. , Dika, Imane H. El, Abou‐Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. , Bekaii‐Saab, Tanios , Tam, Vincent C. , Zemla, Tyler , Venook, Alan P. , Bertagnolli, Monica M. , Meyerhardt, Jeffrey A. , O’Reilly, Eileen M.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e16107-e16107

10.1200/jco.2018.36.15_suppl.e16107 Get It

Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).
Das, Rahul K, Innocenti, Federico , Cunha, Daniel Ferreira da , Rich, Kelly , Lenz, Heinz‐Josef , Niedzwiecki, Donna , Wuest, Diane, Hayete, Boris , Khalil, Iya, Niedzwiecki, Donna , Das, Rahul K, Furchtgott, Leon , Meyerhardt, Jeffrey A. , Nixon, Andrew B. , Cunha, Daniel, Rich, Kelly, O’Reilly, Eileen M. , Ou, Fang‐Shu , Latourelle, Jeanne C. , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3570-3570

10.1200/jco.2018.36.15_suppl.3570 Get It

Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial.
Liu, Glenn , Jarrard, David F. , García, Jorge A. , Hussain, Maha , Eisenberger, Mario A. , Hahn, Noah M. , DiPaola, Robert S. , Harshman, Lauren C. , Hussain, Maha H A , Bryce, Alan H. , Chen, Yu‐Hui , Carducci, Michael A. , Dreicer, Robert , Kohli, Manish , Plimack, Elizabeth R. , Vogelzang, Nicholas J. , Picus, Joel , Sweeney, Christopher J.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5046-5046

10.1200/jco.2018.36.15_suppl.5046 Get It

Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
Twohy, Erin , Meyers, Michael O. , Boffa, Daniel J., Mitchell, Kisha A. , Ilson, David H. , Goodman, Karyn A. , Hall, Nathan C. , Bekaii‐Saab, Tanios , Ou, Fang‐Shu , Perry, Kyle A. , Frankel, Wendy L. , Venook, Alan P. , O’Reilly, Eileen M.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4012-4012

10.1200/jco.2018.36.15_suppl.4012 Get It

A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers
Zhang, Ming , Ferrari, Raffaele, Tartaglia, Maria Carmela , Keith, Julia , Surace, Ezequiel , Wolf, Uri, Sato, Christine , Grinberg, Mark, Liang, Yan , Xi, Zhengrui, Dupont, Kyle, McGoldrick, Philip, Weichert, Anna , McKeever, Paul M. , Schneider, Raphaël , McCorkindale, Michael D, Manzoni, Claudia , Rademakers, Rosa , Graff, Caroline , Parisi, Joseph E., Petersen, Ronald C., Miller, Bruce L. , Rooij, Jeroen van , Pijnenburg, Yolande A.L. , Zee, Julie van der, Broeckhoven, Christine Van , Ber, Isabelle Le , Deerlin, Vivianna Van, Suh, EunRan , Rohrer, Jonathan D. , Mead, Simon , Öijerstedt, Linn , Pickering‐Brown, Stuart , Rollinson, Sara, Rossi, Giacomina , Tagliavini, Fabrizio , Brooks, William S. , Dobson‐Stone, Carol , Halliday, Glenda M. , Hodges, John R. , Piguet, Olivier , Binetti, Giuliano , Benussi, Luisa , Ghidoni, Roberta , Sorbi, Sandro , Bruni, Amalia C. , Galimberti, Daniela , Rainero, Innocenzo , Rubino, Elisa , Lleó, Alberto, Ruiz, Agustı́n , Hernández, Isabel, Pástor, Pau , Díez-Fairén, Mónica , Borroni, Barbara , Pasquier, Florence , Deramecourt, Vincent , Lebouvier, Thibaud , Perneczky, Robert , Diehl‐Schmid, Janine , Huey, Edward D. , Mayeux, Richard , Nalls, Michael A., Hernandez, Dena G., Singleton, Andrew B., Momeni, Parastoo, Zeng, Zhen , Hardy, John , Zinman, Lorne , Nalls, Michael A., Ramasamy, Adaikalavan , Hodges, John R. , Bartley, Lauren, Hernández, Isabel, Boada, Merçé , Padovani, Alessandro , Cairns, Nigel J. , Serpente, María , Scarpini, Elio, Blesa, Rafael , ouml, Maria Landqvist Wald, Nilsson, Karin , Mackenzie, Ian R. , Hsiung, Ging‐Yuek Robin , Attems, Johannes , Pietrini, Pietro , Baborie, Atik, Jaros, Evelyn, Tierney, Michael C, Razquín, Cristina , Ortega‐Cubero, Sara , Alonso, Elena, Alexopoulos, Panagiotis , Kurz, Alexander , Pinessi, Lorenzo , Rogaeva, Ekaterina, Giaccone, Giorgio , Rowe, James B. , Uphill, James, Collinge, John, Danek, Adrian , Deerlin, Vivianna M Van, Grossman, Murray, Trojanowski, John Q. , Leber, Isabelle, Hannequin, Didier , Golfier, Véronique, Vercelletto, Martine, Brice, Alexis , Nacmias, Benedetta, Bagnoli, Silvia , Hjermind, Lena E. , Riemenschneider, Matthias, Mayhaus, Manuel, Ibach, Bernd, Gasparoni, Gilles, Pichler, Sabrina, Fox, Nick C. , Warren, Jason D. , Spillantini, Maria Grazia , Rizzu, Patrizia , Heutink, Peter , Snowden, Julie S. , Richardson, Anna , Maletta, Raffaele , Frangipane, Francesca, Bernardi, Livia , Conidi, Maria Elena, Smirne, Nicoletta , Rademakers, Rosa, Baker, Matt , Petersen, Ronald , Knopman, David, Josephs, Keith A. , Miller, Bruce L., Karydas, Anna M., Rosen, Howard J., Scheltens, Philip , Logroscino, Giancarlo , Capozzo, Rosa , Novelli, Valeria , Franceschi, M. , Postiglione, Alfredo, Milan, Graziella , Sorrentino, Paolo, Kristiansen, Mark, Chiang, Huei-Hsin, Rollin, Adeline, Deramecourt, Vincent, Kapogiannis, Dimitrios , Waldö, Maria Landqvist , Halliday, Glenda , Logroscino, Giancarlo , Rowe, James B , Hsiung, Gink-Yuek , Miller, Bruce L , Hardy, John , Scheltens, Philip , Rohrer, Jonathan D , Fox, Nick C , Padovani, Alessandro , Ruiz, Agustín , Pastor, Pau , Boada, Merce , Tartaglia, Maria Carmela , Pasquier, Florence , Brooks, William , McGoldrick, Philip , McCorkindale, Michael , Dickson, Dennis W. , Boeve, Bradley F. , Seeley, William W. , Swieten, John C. van , Zee, Julie van der , Deerlin, Vivianna M. Van , Nacmias, Benedetta , Scarpini, Elio , Clarimón, Jordi , Lleó, Alberto , Grafman, Jordan Henry , Robertson, Janice , Rogaeva, Ekaterina A. , Kwok, John B. , Schofield, Peter R. , Thompson, Elizabeth A. , Cruchaga, Carlos , Forloni, Gianluigi , Albani, Diego , Fenoglio, Chiara , Nilsson, Christer, Mann, David , Morris, Christopher M. , Griffiths, Timothy David , McKeith, Ian G. , Thomas, Alan , Wassermann, Eric M. , Tierney, Michael C, George‐Hyslop, Peter St , Schlachetzki, Johannes C. M. , Cappa, Stefano F. , Piaceri, Irene , Nielsen, Jørgen Erik , Riemenschneider, Markus J. , Gu, Wei , Rossor, Martin N. , Morris, Huw R. , Gerhard, Alexander , Cupidi, Chiara , Anfossi, Maria , Gallo, Maura , Dopper, Elise G.P. , Seelaar, Harro , Puca, Annibale Alessandro , Franceschi, Massimo, Chiang, Huei‐Hsin, Ferrucci, Luigi , Brice, Alexis , Rainero, Innocenzo , Galimberti, Daniela , Pijnenburg, Yolande A L , Lebouvier, Thibaud , Graff, Caroline , Borroni, Barbara

Mayo Clinic

Brain | August 31, 2018 | Volume: 141 | Issue: 10 | Pages: 2895-2907

10.1093/brain/awy238 | PMID 30252044 Get It

NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial
Mayo, Marlyn J. , Wigg, Alan , Leggett, Barbara , Arnold, Hays, Thompson, Alexander , Weltman, Martin , Carey, Elizabeth J. , Ling, Lei , Rossi, Stephen J., DePaoli, Alex M. , Muir, Andrew Joseph , Rossi, Stephen J.

Mayo Clinic

Hepatology Communications | August 30, 2018 | Volume: 2 | Issue: 9 | Pages: 1037-1050

10.1002/hep4.1209 | PMID 30202819 Get It

Patients with primary biliary cholangitis (PBC) who had an inadequate response to ursodiol have few treatment options. Alkaline phosphatase (ALP) and bilirubin levels correlate with the risk of liver transplant or death in PBC patients. Fibroblast growth factor (FGF) 19 is a hormone that acts directly in the liver to regulate bile acid synthesis. We evaluated NGM282, an engineered analogue of FGF19, for the treatment of PBC. In this 28‐day, double‐blind, placebo‐controlled phase 2 trial, 45 PBC patients who had an inadequate response to ursodiol were randomly assigned 1:1:1 to receive subcutaneous daily doses of either NGM282 at 0.3 mg (n = 14), 3 mg (n = 16), or placebo (n = 15). The primary endpoint was a change in ALP from baseline after 28 days of treatment. At day 28, ALP was significantly reduced with NGM282 treatment at both 0.3 mg (least‐squares mean –51.0 IU/L [standard error (SE) 15.4]) and 3 mg (–66.0 IU/L [SE 16.0]) versus placebo (3.3 IU/L [SE 14.8]), with least‐squares mean differences of –54.3 IU/L (95% confidence interval –104.2 to –4.5; P = 0.0149) and –69.3 IU/L (95% confidence interval –120.5 to –18.3; P = 0.0030), respectively. Fifty percent (7 of 14) of patients receiving NGM282 0.3 mg and 46% (6 of 13) of those receiving NGM282 3mg achieved 15% or greater reduction in ALP levels from baseline, compared with 7% (1 of 15) of patients receiving placebo. NGM282 also significantly reduced serum concentrations of transaminases and immunoglobulins. Most adverse events were grade 1 (mild) to grade 2 (moderate) in severity, with gastrointestinal disorders more frequent in the NGM282 treatment groups. No worsening of pruritus was observed with NGM282 treatment. Conclusion: NGM282 administered for 28 days resulted in significant improvements in ALP and transaminase levels compared with placebo, with an acceptable safety profile in patients with PBC. (Hepatology Communications 2018; 00:000‐000)
Presentation and outcomes of patients with thoracic and lumbosacral spinal epidural arteriovenous fistulas: a systematic review and meta-analysis
Byun, Jun Soo , Tsang, Anderson Chun On , Hilditch, Christopher Alan , Nicholson, Patrick , Brinjikji, Waleed , Fang, Yi-Bin , Krings, Timo , Mendes Pereira, Vitor , Lanzino, Giuseppe

Mayo Clinic

Journal of NeuroInterventional Surgery | August 30, 2018 | Volume: 11 | Issue: 1 | Pages: 95-98

10.1136/neurintsurg-2018-014203 | PMID 30166334 Get It

Background and purpose Thoracolumbar and sacral spinal epidural arteriovenous fistulas (SEDAVFs) are an increasingly recognized form of spinal vascular malformation. The purpose of this study was to perform a systematic review of the demographics, clinical presentation and treatment results of thoracolumbar SEDAVFs. Materials and methods Pubmed, Scopus and Web of Science databases were searched from January 2000 to January 2018 for articles on treatment of SEDAVFs. Pooled data of individual patients were analyzed for demographic and clinical features of SEDAVFs as well as treatment outcomes. Results There were 125 patients from 11 studies included. Mean age was 63.5 years. There was a male sex predilection (69.6%). Sensory symptoms including pain or numbness were the most frequently presenting symptoms. Fistula location was the lumbosacral spine in 79.2% and the thoracic spine in 20.8%. Involvement of intradural venous drainage was more common than extradural venous drainage only (89.6% vs 10.4%). Of the 123 treated patients, endovascular therapy was performed in 67.5% of patients, microsurgery in 23.6%, and combined treatment in 8.9%. The overall complete obliteration rate was 83.5% and did not differ between groups. Clinical symptoms improved in 70.7% of patients, were stable in 25%, and worsened in 1.7% with no difference between treatment modalities. Conclusions Thoracic and lumbosacral SEDAVFs often present with symptoms secondary to congestive myelopathy or compressive symptoms. Both endovascular and microsurgical treatments were associated with high obliteration rates and good clinical outcomes.
Composite Hydrogel Embedded with Porous Microspheres for Long-Term pH-Sensitive Drug Delivery
Liu, Xifeng , Fundora, Kevin A. , Zhou, Zifei , Lu, Lichun , Miller, Alan Lee, Miller, Alan Lee

Mayo Clinic

Tissue Engineering Part A | August 30, 2018 | Volume: 25 | Issue: 3-4 | Pages: 172-182

10.1089/ten.tea.2018.0071 | PMID 30152721 Get It

Current delivery of chemotherapy drugs to osteosarcoma is limited by the difficulties in overcoming the solid tumor microenvironment and the cardiotoxicity of doxorubicin (DOX). In previous work we found that phase separation could generate microspheres with high porosity. In this study, we applied these phase-separated porous microspheres as carriers for long-term anticancer drug delivery. Novel poly(propylene fumarate)- co -poly( l -lactic acid) microspheres incorporating DOX were fabricated by thermally induced phase separation. Following embedding into oligo(poly[ethylene glycol] fumarate) hydrogel, the composite system showed prolonged and pH-responsive release of DOX. In vitro cytotoxicity study using osteosarcoma 143B cells showed substantial long-term cytotoxic effects for up to 30 days. As a result, the DOX drug delivery hydrogel developed in this work may have significant potential as a long-term and localized chemotherapy device that would be sensitive to the acidic microenvironment of osteosarcoma and other cancers. Impact Statement A composite hydrogel embedded with porous microspheres fabricated by phase separation methods was developed and showed excellent long-term anticancer drug delivery capability to cancer cells.